Diagnosis And Management Of Antithyroid Drug Induced Agranulocytosis
DOI:
https://doi.org/10.29103/micohedmed.v1i1.27Keywords:
Diagnosis, antithyroids, agranulocytosisAbstract
Agranulocytosis as adversed effect of antithyroid drug (ATD) in patients with Graves disease is a rare complication but it can be serious and life threatening. The mortality rate 2-10% caused by severe infection as complications. Immediate diagnosis and management are essential for proper treatment and good prognosis. A 35-year-old female with Graves disease was complaining of fever and sore throat. She was initially treated with Thiamizole 1x20 mg for 2 weeks. Physical examination revealed leukoplakia and diffuse struma. Laboratory test : FT4 43 pmol/L, TSHs :0,005 uIu/mL, ANC <100/ul. Patient is diagnosed with ATD induced agranulocytosis. Treatment includes meropenem, fluconazole and GCSFs. The clinical and laboratory parameter improved after two weeks of treatment. Agranulocytosis in Graves’ disease patient which had ATD is a rare occurrence, with an incidence 0,2- 0,5% (66,7% had severe infection). The diagnostic criteria for agranulocytosis caused by ATD are hyperthyroid patients who are confirmed with an increase T4 and/or T3, decrease in TSH, ANC of 1500/ul before receiving ATD, ANC < 500/ul after initiation ATD and other causes of agranulocytosis have been excluded. In fact, most patients had ANC <100/ul. There are no symptom difference with agranulocytosis caused by other cause. High fever and sore throat are the most common symptom. Initial management are to identify, immediately stop the drug use, broad spectrum antibiotics and GCSFs. The hyperthyroidism will continue and alternative therapies should still be given. The best prevention is to educate patient and to examine granulocyte count frequently.
References
Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for The Management of Grave’s Hyperthyroidism. European Thyroid Journal. 2018;7:167-186.
Wells BG, DiPiro JT, Schwinghammer TL, DiPiro CV. Pharmacoterapy Handbook. 9th Ed. North America: The McGraw Hill Education. 2015:179.
Lavin, N. Manual of Endocrinology and Metabolism. 5th Ed. Philadelphia: Wolters Kluwer. 2019.
Camacho PM, Gharib H, Sizemore GW. Evidence-Based Endocrinology. 4th Ed. Philadelphia: Wolters Kluwer. 2020:51.
Gardner DG, Shoback D. Greenspan's Basic & Clinical Endocrinology. 10th Ed. North America: A Lange Medical Book. 2018:211.
Jameson JL. Harrison's Endocrinology. 4th Ed. North America: McGraw-Hill Education. 2013:68-88.
Vicente N, Cardoso L, Barros L, Carrilho F.Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and Management. Drugs in R and D. 2017:17(1): 91–96.
Kim HK, Yoon JH, Kim TY, Shong YK, Lee MJ, Kim BH, et al. Characteristics of Korean patients with antithyroid drug-induced agranulocytosis: A multicenter study in Korea. Endocrinology and Metabolism. 2015:30(4):475–480.
Spears E. Antithyroid Drug-Induced Agranulocytosis. Nursing Student Class Projects (Formerly MSN). 2015:85.
Chaudhry LA. Antithyroid drug induced a granulocytosis: What still weneed tolearn?. Pan African Medical Journal. 2016;1–6.
American Thyroid Association. Antithyroid Drug-Induced Agranulocytosis is about 10- fold More Common in Amiodarone-Induced Thyrotoxicosis than in Thyrotoxicosis due to Other Causes. Clinical Thyroidology for the Public. 2019:12(7).
Arch Bronconeumol. Thiamazole-Induced Agranulocytosis Leading to Abscessus Pneumonia-Rare, But Challenging. Elsevier Espana. 2018:289-290.
Yang J, Zhang J, Xu Q, Sheng GP, Weng WW, Dong MJ. Unusual Synchronous Methimazole-induced Agranulocytosis and Severe Hepatotoxicity in Patient with Hyperthyroidism: A Case report and review of the literature. International Journal of Endocrinology. 2015.
Yang J, Zhu YJ, Zhong JJ, Zhang J, Weng WW, Liu ZF, et al. Characteristics of Antithyroid Drug-Induced Agranulocytosis in Patients with Hyperthyroidism: A Retrospective Analysis of 114 Cases in A Single Institution in China Involving 9690 Patients Referred for Radioiodine Treatment over 15 Years. Thyroid. 2016:26(5).
Rabelo PN, Paula AF, Canceicao SA, Viggiano DP, Antunes DE, et al. Propylthiouracil- induced Agranulocytosis as a rare Complication of Antithyroid Drugs in a patient with Graves’ disease. Revista da Associacao Medica Brasileira. 2019: 65(6):755–760.
Nakamura H, Ide A, Kudo T, Nishihara E, Ito M, Miyauchi A. Periodic Granulocyte Count Measuring Is Useful for Detecting Asymptomatic Agranulocytosis in Antithyroid
Drug-Treated Patients with Graves’ Disease. European Thyroid Journal. 2016:5(4): 253– 260.
American Thyroid Association. Can We Predict Which Patients with Hypertiroidism will Develop Agranulocytosis with Antithyroid Drugs?. Clinical Thyroidology for the Public. 2016:9(11).
Kim H, Lee J, Ha J. A Case of Antithyroid Drug-induced Agranulocytosis from a Second Antithyroid Drugs (ATD) Administration in a Relapsed Graves’ Disease Patient Who Was Tolerant to The First ATD Treatment. Clinical Case Reports. 2018:6(9): 1701–1703
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
n order for Proceedings of Malikussaleh International Conference on Health and Disaster Medicine (MICOHEDMED) to publish and disseminate research articles, we need non-exclusive publishing rights (transfered from author(s) to publisher). This is determined by a publishing agreement between the Author(s) and Proceedings of Malikussaleh International Conference on Health and Disaster Medicine (MICOHEDMED). This agreement deals with the transfer or license of the copyright of publishing to Proceedings of Malikussaleh International Conference on Health and Disaster Medicine (MICOHEDMED), while Authors still retain significant rights to use and share their own published articles. Proceedings of Malikussaleh International Conference on Health and Disaster Medicine (MICOHEDMED) supports the need for authors to share, disseminate and maximize the impact of their research and these rights, in any databases.
As a proceeding Author, you have rights for a large range of uses of your article, including use by your employing institute or company. These Author rights can be exercised without the need to obtain specific permission. Authors publishing in Proceedings of Malikussaleh International Conference on Health and Disaster Medicine (MICOHEDMED) proceedings have wide rights to use their works for teaching and scholarly purposes without needing to seek permission, including:
- use for classroom teaching by Author or Author's institution and presentation at a meeting or conference and distributing copies to attendees;
- use for internal training by author's company;
- distribution to colleagues for their reseearch use;
- use in a subsequent compilation of the author's works;
- inclusion in a thesis or dissertation;
- reuse of portions or extracts from the article in other works (with full acknowledgement of final article);
- preparation of derivative works (other than commercial purposes) (with full acknowledgement of final article);
- voluntary posting on open web sites operated by author or author’s institution for scholarly purposes,
(but it should follow the open access license of Creative Common CC-by-SA License).
Authors/Readers/Third Parties can read, print and download, redistribute or republish the article (e.g. display in a repository), translate the article, download for text and data mining purposes, reuse portions or extracts from the article in other works, sell or re-use for commercial purposes, remix, transform, or build upon the material, they must distribute their contributions under the same license as the original Creative Commons Attribution-ShareAlike (CC BY-SA).
